Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

• Main Authors: Neil Goldstein (Author), Chelsea McLean (Author), Auguste Gaddah (Author), Joachim Doua (Author), Babajide Keshinro (Author), Linda Bus-Jacobs (Author), Jenny Hendriks (Author), Kerstin Luhn (Author), Cynthia Robinson (Author), Macaya Douoguih (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTThis phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consecutively manufactured lots of Ad26.ZEBOV on Day 1 p...